{"analyses":[{"ciLowerLimit":"0.711","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.123","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.3342","paramType":"Hazard Ratio (HR)","paramValue":"0.893","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"3.1","value":"2.2"},{"groupId":"OG001","lowerLimit":"1.5","upperLimit":"2.4","value":"1.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"451"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"description":"Defined as time from randomization to confirmed deterioration (10-point change) on the combined European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core (EORTC QLQ-C30) and supplemental lung cancer module (EORTC QLQ-LC13) symptom subscales.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.","id":"OG001","title":"Arm B (Nab-Paclitaxel+Carboplatin)"}],"paramType":"MEDIAN","populationDescription":"The ITT- WT population was defined as the ITT population excluding participants with an activating EGFR mutation or ALK translocation.","reportingStatus":"POSTED","timeFrame":"Up to approximately 35 months after first subject enrolled","title":"Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms in the ITT-WT Population","type":"SECONDARY","unitOfMeasure":"Months"}